Abstract
The 5-hydroxytryptamine (5-HT)1A receptor system plays a prominent role in a variety of physiological functions and behaviors and regulation of the responsiveness of this receptor system has been implicated in the therapeutic mechanism of action of the selective serotonin reuptake inhibitor class of antidepressant drugs. Here we report that the responsiveness of the 5-HT1A receptor system is regulated by consequences of activation of the phospholipase A2 (PLA2) and phospholipase C effector pathways. In Chinese hamster ovary cells stably expressing the human 5-HT1A receptor, 5-HT1A receptor-mediated inhibition of forskolin-stimulated cAMP accumulation was reduced by a cyclooxygenase-dependent arachidonic acid (AA) metabolite produced in response to exogenously applied AA or activation of PLA2directly with melittin or indirectly by receptor activation. This effect of the AA metabolite was sensitive to the activation state of adenylyl cyclase suggesting that the target of the AA metabolite-induced reduction in 5-HT1A responsiveness was adenylyl cyclase. Activation of protein kinase C with a phorbol ester also reduced 5-HT1A receptor function. In contrast, increases in intracellular calcium levels via a calcium ionophore or thapsigargin enhanced 5-HT1A responsiveness. The net effect of activation of phospholipid-coupled receptors on 5-HT1Aagonist efficacy depended upon the relative capacity to produce these positive (calcium) and negative (AA) regulators. These data demonstrate that the responsiveness of the 5-HT1A receptor system can be enhanced or depressed by consequences of activation of phospholipid-coupled receptor systems. An understanding of the cellular mechanisms for regulation of 5-HT1A function may lead to novel targets for development of psychotherapeutic drugs.
Footnotes
-
Send reprint requests to: Kelly A. Berg, Department of Pharmacology, Mail Code 7764, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900. E-mail:berg{at}uthscsa.edu
-
↵1 Present address: University of Houston, Department of Pharmacological and Pharmaceutical Sciences, 4800 Calhoun, Houston, TX 77204-5515.
-
This work was supported by United States Public Health Service Grants DA 09094 (to K.A.B.), MH 57441 (to W.P.C.), and MH 48125 (to W.P.C.). Part of this work was submitted to the University of Texas Health Science Center at San Antonio for partial fulfillment for the requirements for the Ph.D. degree (K.L.J.E.).
- Abbreviations:
- 5-HT
- 5-hydroxytryptamine, serotonin
- SSRI
- selective serotonin reuptake inhibitor
- AA
- arachidonic acid
- FSK
- forskolin
- dp-5-CT
- dipropyl 5-carboxamidotryptamine
- DOI
- (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
- 5-CT
- 5-carboxadmidotryptamine
- 8-OH-DPAT
- 8-hydroxy-dipropylaminotetralin
- BAPTA-AM
- 1,2-bis-(o-aminophenoxy)-ethane-N,N,N′,N′-tetraacetic acid tetra(acetoxymethyl) ester
- p-MPPF
- 4-(2′-methoxyphenyl)-1-[2′-(N-2"-pyridyl)-p-fluorobenzamido] ethylpiperazine
- HBSS
- Hanks' balanced salt solution
- CHO
- Chinese hamster ovary
- FScA
- forskolin-stimulated cAMP accumulation
- BSA
- bovine serum albumin
- DMSO
- dimethyl sulfoxide
- [Ca2+]i
- intracellular calcium
- Gpp(NH)p
- nucleotide guanosine 5′-(β,γ-imino) triphosphate
- PLA2
- phospholipase A2
- PLC
- phospholipase C
- PKC
- protein kinase C
- Received November 28, 2000.
- Accepted February 9, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|